Latest Breaking News On - Eduardo redondo cerezo - Page 1 : vimarsana.com

Patients who switched from originator adalimumab to a biosimilar experienced more treatment-emergent adverse events compared to those who stuck with the biosimilar or the reference drug.

Eduardo redondo cerezoLinkedin eduardo redondo cerezoUniversity of grenadaVirgen de las nieves university hospitalInflammatory bowel diseaseUlcerative colitisCrohn x27s disease